Bio Path Holdings Inc
NASDAQ:BPTH
Bio Path Holdings Inc
Inventory
Bio Path Holdings Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bio Path Holdings Inc
NASDAQ:BPTH
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Inventory
$5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Inventory
$1.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Inventory
$6.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Inventory
$1.7B
|
CAGR 3-Years
54%
|
CAGR 5-Years
43%
|
CAGR 10-Years
40%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Inventory
$2.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
Bio Path Holdings Inc
Glance View
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The company is headquartered in Bellaire, Texas and currently employs 10 full-time employees. The company went IPO on 2006-01-11. The company utilizes a technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead drug candidate, prexigebersen, targets growth factor receptor-bound protein 2 (Grb2). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein. Its modified product named prexigebersen-A, is its fourth drug candidate.
